Livingstone Health looks beyond Sinovac boost; to broaden range of services
The multi-disciplinary healthcare group does not want to specialise too narrowly.
BEING appointed to lead Sinovac procurement for Singapore's private healthcare institutions might be seen as something of a coup for Livingstone Health Holdings. But chief executive officer Wilson Tay does not wish to overstate the significance of that Covid-19 vaccine's contribution to the healthcare group's prospects.
Seeing it more as "national service", he considers it a non-core part of Livingstone's business - although the healthcare group's "core business" is itself very diverse.
In the half-year ended Sep 30, revenue from the company's family medicine segment rose S$2.2 million "mainly due to the revenue generated from sale and administration of (the) Sinovac vaccine in September 2021". Subsidiary Livingstone Health International had been appointed to do so by the Health Ministry that month.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Luminar to cut nearly 20% jobs as part of restructuring
TD risks an earnings hit from US laundering probe, analysts say
Everything Apple plans to show at May 7 ‘let loose’ iPad event
BNP weighing up to 150 job cuts in Geneva to slash costs
Bitcoin’s wild price swings point to the rising influence of ETF buyers
Paramount will let exclusive talks with Skydance lapse: NYT